Transthyretin Amyloid Cardiomyopathy Risk Evaluation in a Cohort of Patients With Heart Failure
The Permanente Journal · 15.06.2023 · 27 (2) · 51-60
DOI: 10.7812/tpp/22.135 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Permanente Journal, erschienen am 15.06.2023. Verfasst von Angie A Suh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO, USA. Hauptthemen laut MEDLINE: Cardiomyopathies, Amyloid Neuropathies, Familial, Heart Failure, Atrial Fibrillation. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO, USA.
- Cardiology Department, Colorado Permanente Medical Group, Aurora, CO, USA.
- Cardiology Department, Colorado Permanente Medical Group, Saint Joseph Hospital, Denver, CO, USA.
- Pharmacy Outcomes Research Group, Kaiser Permanente National Pharmacy, Aurora, CO, USA.
ORCID-Profile: Thomas Delate
Zitieren
APA
Suh, A. A., Shaw, P. B., Jeong, M. Y., Olson, K. L., & Delate, T. (2023). Transthyretin Amyloid Cardiomyopathy Risk Evaluation in a Cohort of Patients With Heart Failure. The Permanente Journal, 27(2), 51-60. https://doi.org/10.7812/tpp/22.135
Vancouver
Suh AA, Shaw PB, Jeong MY, Olson KL, Delate T. Transthyretin Amyloid Cardiomyopathy Risk Evaluation in a Cohort of Patients With Heart Failure. The Permanente Journal. 2023;27(2):51-60. doi:10.7812/tpp/22.135
BibTeX
@article{Suh2023,
author = {Suh, Angie A and Shaw, Paul B and Jeong, Mark Y and Olson, Kari L and Delate, Thomas},
title = {Transthyretin Amyloid Cardiomyopathy Risk Evaluation in a Cohort of Patients With Heart Failure},
journal = {The Permanente Journal},
year = {2023},
volume = {27},
number = {2},
pages = {51--60},
doi = {10.7812/tpp/22.135}
}
EUVIMED